Marjorie O'Neill

Cooley advised the underwriters of Shoulder Innovations, a medical technology company exclusively focused on transforming the shoulder surgical care market, in connection with Shoulder Innovations’ $75 million initial public offering (IPO).

Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.

Cooley advised Mirum Pharmaceuticals on its $275 million aggregate principal amount of 4.00% convertible senior notes due 2029. Mirum is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Jason Kent and Jason Savich led the Cooley team.

Cooley advised the underwriters in Pliant Therapeutics’ $230.0 million follow-on offering of 12,432,432 shares of common stock at a public offering price of $18.50 per share. Pliant is a clinical-stage biotechnology company discovering and developing novel therapies for the treatment of fibrosis. Partners Denny Won, Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team.

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.